GE Capital rolling out enhanced digital tools to address site selection issues
SCOTTSDALE, AZ --- Restaurant franchise owners looking to grow their portfolios say that obtaining quality data is their biggest problem when looking for new sites, according to a recent survey by GE Capital, Franchise Finance (GEFF), a leading provider of financing to restaurant owners.
Analysis of Multiplexed Proteins at Single-Cell Level Provides a Deeper Understanding of Cancer
ALISO VIEJO, CA, December 9, 2013 -- GE Healthcare today announced results from two studies that show how using the MultiOmyx™ Hodgkin Lymphoma (HL) Profile and an investigational profile for breast cancer may improve assessment of the two diseases in subsets of patients.
Expanded wholesale relationship benefits dealers across Canada as network grows
MISSISSAUGA, ON --- GE Capital's Commercial Distribution Finance (CDF) business announced today that it has been named the preferred inventory financing provider for Visionary Motorsports Ltd., expanding a relationship that began in 2008.
Winning entry to be mass-produced as a Christmas ornament and given away as part of GE's celebration of the first-ever "3D Printing Day", December 3.
NISKAYUNA, NY, December 2, 2013 -- GE Global Research, the technology development arm of the General Electric Company (NYSE: GE), today announced that a winner has been chosen in its Santa Sleigh 3D printing design contest/GRABCAD challenge, a first-time event bringing together the maker community for some holiday fun in advance of tomorrow's inaugural 3D Printing Day.
GE demonstrates the "Power of Partnership" through innovative technologies that improve patient care, comfort and productivity
As the 99th annual meeting of the Radiological Society of North America (#RSNA13) opened today, GE Healthcare, a unit of General Electric Company (NYSE:GE), demonstrated its commitment to delivering innovative healthcare technologies to solve clinicians' most pressing challenges in patient care, comfort and productivity.
Princeton, NJ -- November 27, 2013 -- GE Healthcare today announced results from a new study, which showed that patients receiving Visipaque™ (iodixanol 320mg I/ml) were less likely to experience discomfort, characterized by heat or cold sensation or pain upon injection, than patients receiving Isovue® (iopamidol 370 mg I/ml). As with other iodinated contrast agents, Visipaque is often associated with sensations of discomfort, heat or pain. The data were published online in Acta Radiologica.[i]
